How to analyze the company?LEARNWhat should you know before buying?
Get a brief AI stock analysisSaves ~ 15 minutes of your time

GB

OOTC:GBIM
Get a brief AI stock analysisSaves ~ 15 minutes of your time

GB

Globeimmune IncOOTC GBIM Stock Report

Get a brief AI stock analysis
Saves ~ 15 minutes of your time

Price

Market cap $B

Exchange

OOTC - OTC

FAIR VALUE

Is GBIM undervalued compared to its fair value?

The fair value of GBIM stock is hidden USD. Relative to the market price of 0 USD Globeimmune Inc is hidden.

GlobeImmune Inc. is a biopharmaceutical company. The Company is focused on developing products for the treatment of cancer and infectious diseases based on its Tarmogen platform. The Company’s Tarmogen platform activates...[More about valuation]

Globeimmune Fair Value

hidden
UNLOCK
What is fair value?

Market cap:

0 $B

Price:

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

-0.15

FINANCIALS

Globeimmune financial for reporting period

Income Statement

0.0009 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.0009 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.0009 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

0.0009 B 100%
0.0009 B 100%
-0.0009 B -91%
-0.0009 B -91%

Balance Sheet

0.0098 B
0.0022 B

Financial Position Analysis

Assets

0.0098 B
Current Assets
0.0095 B
Total non-current assets
0.0003 B

Total current liabilities
0.0041 B
Total non-current liabilities
0.0035 B

Cash Flow Statement

-N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.0012 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Globeimmune fundamental analysis for trailing twelve months (TTM)

Profitability Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators

-71 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-17 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Is GBIM attractive for investment based on fundamental analysis?

GBIM stock rating is hidden. Globeimmune is a hidden by Eyestock methodology.

Get GBIM Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

-33

Gross Margin:

98

CFO / Debt ratio:

hidden

Current ratio:

2.665

Debt / Equity ratio:

ROE:

-71

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

GBIM analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for GBIM to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

Globeimmune Inc competitors

AB

ABBV

Abbvie Inc

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Ill...

Discover

AM

AMGN

Amgen Inc

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company...

Discover

VR

VRTX

Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs fo...

Discover

Globeimmune Inc dividends

GBIM dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About GBIM stock

About the company Globeimmune Inc

Market cap $B

0

Dividend yield

Shares outstanding

5.75 B

GlobeImmune Inc. is a biopharmaceutical company. The Company is focused on developing products for the treatment of cancer and infectious diseases based on its Tarmogen platform. The Company’s Tarmogen platform activates the immune system by stimulating a subset of white blood cells called T cells that destroy infected or malignant cells in contrast to traditional vaccines, which predominately stimulate antibody production. Tarmogens also reduce the number and function of regulatory T cells, thus further enabling the antigen-specific cellular immune response. It has over two Tarmogen product candidates in clinical evaluation for infectious disease and multiple cancer indications. The Company's oncology product candidates include GI-6301, GI-6207 and GI-4000. The Company's infectious disease product candidates include GS-4774, GI-19000, GI-2010 and GI-18000.

GBIM profile

  • Ticker

    GBIM

  • Country

    USA

  • Exchange

    OOTC - OTC

  • Report currency

    USD - US dollar

  • IPO date

    02 July 2014

  • Sector

    Healthсare

  • Industry

    Biotechnology

  • Employees

  • City

    Louisville

  • Address

    1450 Infinite Drive

  • Cusip

    37957B100